Turn Biotechnologies

What it is

Turn Biotechnologies developed a platform called ERA (Epigenetic Reprogramming of Aging) that delivers transient mRNA encoding partial Yamanaka factors to specific tissues. The transience reduces the identity-loss and tumourigenesis risks associated with sustained factor expression.

Initial focus

• Skin (in collaboration with major cosmetics companies for topical anti-aging products).
• Hair follicle rejuvenation.
• Joint cartilage for osteoarthritis.
• Optic-nerve programmes for glaucoma.

Why mRNA delivery

• No DNA integration.
• Tunable, transient expression window.
• Tissue-targeted delivery via lipid nanoparticles.
• Easier safety profile than AAV gene therapy.

State

Pre-clinical / early translational. The skin/cosmetic programmes have a nearer path to consumer products than the disease-modifying programmes.

Why it matters

Turn represents a middle path between systemic gene therapy (Rejuvenate Bio) and the long-horizon basic-science programmes (Altos). Tissue-specific transient reprogramming may reach products earlier in selected indications.

Related entries

Partial reprogramming, Information theory of aging, Altos Labs.